A whole-plant cannabis extract and a pure 1:1 THC:CBD mixture produced distinct pain-relief profiles and engaged different endocannabinoid targets in a rat model of diabetic neuropathy, despite having the same THC:CBD ratio.
Cannabis pharmacology researchers, pain specialists, medical cannabis prescribers
Same THC:CBD ratio, different pain relief profiles and receptor targets
What the researchers found
When injected into the spinal fluid of rats with diabetic neuropathy, a type II cannabis extract and a 1:1 THC:CBD mix produced different antinociceptive responses despite equivalent THC content. The two preparations also engaged CB1, CB2 receptors, and TRPV1 channels differently.
Why it matters
Current medical cannabis prescribing relies heavily on THC:CBD ratios to predict effects. This study suggests that the full composition of an extract matters, not just its major cannabinoid ratio.
The numbers in context
Four conditions tested: pure THC, pure CBD, 1:1 THC:CBD mix, balanced extract; three receptor systems evaluated (CB1, CB2, TRPV1)
How the study worked
Animal study using a rat model of diabetic neuropathy with intrathecal injection of pure THC, pure CBD, a 1:1 THC:CBD mix, and a balanced chemotype II cannabis extract. Receptor involvement assessed using CB1, CB2, and TRPV1 antagonists.
What this study cannot tell us
Animal model with intrathecal (spinal) delivery, which does not reflect typical human routes of administration. Diabetic neuropathy model may not generalize to other pain types. Single extract tested.
How to read the evidence
Animal study with controlled conditions and receptor-level analysis, but spinal delivery route and single extract tested limit clinical translation.
When this study was published
Published 2023
The bigger picture
The finding that same-ratio preparations produce different effects supports the entourage effect concept and challenges the practice of categorizing medical cannabis products primarily by THC:CBD ratio.
Questions still open
- Which minor cannabinoids or terpenes in the whole-plant extract account for the different receptor engagement? Would these differences hold with oral or inhaled administration?
Common questions
Does the THC:CBD ratio predict how a cannabis product will work?
What is the entourage effect?
Read the original research
A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.
Frontiers in pharmacology, 14, 1235255
Citation
Benredjem, Besma; Pineyro, Graciela. (2023). A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.. Frontiers in pharmacology, 14, 1235255. https://doi.org/10.3389/fphar.2023.1235255
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk